Max Rivera: Hey — before we get into it, I have to tell you something that happened that is either very relevant or I'm connecting dots that aren't there. My neighbor's kid had a splinter, and her mom made this whole thing of it — cold compress, counting down, the whole performance — and the kid barely cried. And I kept thinking: was the counting doing something, or was it just distraction?
Clara Bennett: Not just distraction. That's the point we're here to make.
Max Rivera: Yeah — so tell me why.
Clara Bennett: The placebo effect — real definition, not the dismissive one — is measurable physiological and psychological change produced by a treatment with no active pharmacological ingredient, driven by the patient's expectations, learned associations, and the context of how treatment is delivered. The ritual your neighbor created? That's context. And context is not inert.
Max Rivera: Huh. So the countdown wasn't just comfort noise — it was doing actual work.
Clara Bennett: Potentially, yes. And we can trace how seriously medicine takes this back to one paper — Henry Beecher, 1955, 'The Powerful Placebo.' He found roughly one-third of treatment effects in pain and post-surgical recovery could be attributed to placebo. One third. That changed the conversation. After that, randomized controlled trials started requiring placebo controls, and then the placebo arms kept producing non-trivial results — which forced a reckoning.
Max Rivera: A third — that's not a small rounding error you can just wave off.
Clara Bennett: No. And the neuroscience now shows why. Dopamine release in the nucleus accumbens — the brain's core reward center — increases 15 to 20 percent when someone expects pain relief from a placebo. The endogenous opioid system activates. These are real, measurable events. The phrase 'just a placebo' doesn't survive contact with that data.
Max Rivera: So the brain is literally pharmacizing itself based on expectation alone.
Clara Bennett: Exactly that — and the word 'pharmacizing' is actually closer to the truth than most people realize. The brain isn't faking relief. It's dispensing its own medicine. Endorphins, dopamine, serotonin — these are released through the endogenous opioid and dopaminergic pathways, triggered purely by anticipation. Before the pill dissolves. Before anything pharmacologically active has happened.
Max Rivera: Wait — before it dissolves?
Clara Bennett: Before it dissolves. Think of a woman with chronic knee pain sitting in an exam room. The doctor hands her a small white tablet. Her nucleus accumbens — same reward center that fires when you eat something you love or win money — has already started releasing dopamine. She hasn't swallowed it yet. The expectation alone is the key that opens the cabinet.
Max Rivera: Okay that's — I mean, that scrambles something in my head, because I kept thinking of this as the brain overriding pain. But it's not overriding anything, it's more like... the brain just has a medicine cabinet, and believing relief is coming is literally what unlocks it.
Clara Bennett: That's the clean version, yes. One layer stranger — it's also learned. The ritual itself becomes the trigger. The white coat, the calm room, the act of swallowing a pill. Through conditioning — Pavlovian, basically, applied to the nervous system — your brain has associated those cues with relief so many times that the cues alone start producing the response.
Max Rivera: So the counting in my neighbor's kitchen — that was actually... wait, no, is that the same mechanism? Like the kid had learned that counting means it's almost over, so the body just — started unwinding?
Clara Bennett: That's a reasonable read. The ritual maps onto prior experience of relief. The nervous system responds to the signal, not the substance. Pavlov's bell, but the reward is pain reduction instead of food.
Max Rivera: And that means the ritual — the whole therapeutic context, the white coat, the room — that's not set dressing. That's actually doing biological work.
Clara Bennett: It is — and that's exactly where the picture gets uncomfortable. Because the same mechanism that makes context so powerful also exposes the hard ceiling. Hróbjartsson and Gøtzsche — their landmark review — found little evidence that placebos improve objective clinical outcomes compared to no treatment at all. That's not a fringe finding. That's the paper.
Max Rivera: Wait — so we have real dopamine release in the nucleus accumbens, and also a major review saying placebos don't reliably beat doing nothing?
Clara Bennett: Those two findings aren't contradictory. They define a boundary. The brain can gate pain signals in the spinal cord — we can see that on fMRI. It cannot fight a bacterial infection. It cannot knit a fractured bone. The word 'selective' is doing serious work here.
Max Rivera: So a placebo can genuinely reduce how much pain you feel from a fracture while the fracture itself sits there, completely untouched.
Clara Bennett: Exactly that. Perceived pain intensity — measurably down. Underlying tissue damage — unchanged. Those are two separate problems, and the brain only has jurisdiction over one of them.
Max Rivera: That's — I mean, that reframes the whole 'belief heals the body' framing, doesn't it? Because it doesn't. It heals the... the experience of the body, maybe. In some cases.
Clara Bennett: In practice, yes. Hróbjartsson and Gøtzsche found small effects on continuous subjective outcomes — pain scales, nausea ratings — but nothing meaningful on objective endpoints. Blood cultures don't respond to expectation. That's the ceiling.
Max Rivera: So popular placebo stories — the ones that sound like 'mind over matter fixed everything' — those are just hitting the cases where the brain was the modulator all along, and extrapolating.
Clara Bennett: That's the oversell, yes. And there's a layer underneath all of this that makes it stranger still — because it turns out deception might not even be the mechanism, which means the ritual itself could be the active ingredient, and we'll get to what that does to how clinicians are already treating patients without realizing it.
Max Rivera: Wait — deception might not be the mechanism. I can't get past that, because if it's not deception, then what are we even calling this?
Clara Bennett: Open-label placebos. The patient is told explicitly: this is a placebo. No active ingredient. And in some studies, it still works. That's the finding that changes the frame.
Max Rivera: Told outright — and it still does something?
Clara Bennett: Dr. Annabelle Belcher, University of Maryland School of Medicine, 2023. Patients knowingly taking an open-label placebo alongside methadone for opioid use disorder — improved treatment adherence, better sleep quality. The disclosure didn't cancel the effect. Now, the evidence base is still limited, and we don't know yet which conditions generalize. But even the existence of the finding matters.
Max Rivera: I mean, wait. If the patient knows, then the ethical objection — the whole informed consent problem — that basically dissolves, right? The main reason clinicians couldn't just use this disappears.
Clara Bennett: It weakens significantly, yes. Which means the ritual — the appointment, the prescription pad, the clinician who seems to care — those aren't the delivery vehicle for the deception. They're the active ingredient themselves.
Max Rivera: And the nocebo flips that completely dark, doesn't it — because the same pathway that produces relief can run the other direction. A doctor says 'this might cause nausea' and suddenly... it does.
Clara Bennett: Real increased pain. Real side effects. From framing alone, through the same brain-body pathways. Which means clinicians are already dosing patients constantly — through word choice, tone, how long they stay in the room — and most have no idea they're doing it.
Max Rivera: That's — I mean, that's actually a little unsettling. Because it means the Belcher study isn't really about placebos anymore. It's about whether the therapeutic encounter itself is a drug, and nobody's measuring the dose.
Clara Bennett: And I keep turning that over. Researchers working in what they call Contextually Aided Recovery — CARe — have actually described the doctor-patient interaction as a therapeutic tool in its own right. Sensory cues, affective cues, interpersonal cues — all of it reshaping expectation and physiological outcome. Not metaphorically. Functionally. Which means knowing when ritual and expectation are active medicine versus when they're simply irrelevant — that's a clinical skill now. It has to be.
Max Rivera: And the flip side of that is — I mean, every rushed appointment, every diagnosis delivered without warmth, every clinic that's been stripped down to pure efficiency — that's not neutral. That's a nocebo at scale. Nobody called it that. Nobody measured it that way. But by the logic we've been laying out for the last hour, that's what it is.
Clara Bennett: That's genuinely unresolved for me. I can't tell you where the line is between the molecule and the interaction. Medicine has spent a century measuring one and barely touching the other.
Max Rivera: Yeah. I don't think I can either.
Clara Bennett: It's a strange place to land — not a conclusion, just a clearer view of how much we haven't asked. I'm glad we went here.
